Loading...
Uploaded by mdandersonorg on Sep 10, 2010
First clinical trials begin soon to test new drugs against ovarian, endometrial and breast cancers that harbor dysfunctional PI3K pathways. MD Anderson's Gordon Mills explains.
Science & Technology
Standard YouTube License
Load more suggestions
Link to this comment:
All Comments (0)